Risperdal Breast Cancer Lawsuit [June 2026]

Risperdal Breast Cancer Lawsuit Quick Facts

Is the Risperdal Breast Cancer Lawsuit Still Happening?

Yes. Lawsuits are still being filed and actively investigated nationwide by women diagnosed with breast cancer after long-term Risperdal use.

Who May Qualify for a Risperdal Breast Cancer Lawsuit?

Women who were prescribed Risperdal or its generic risperidone for an extended period and subsequently diagnosed with breast cancer may have grounds for a legal claim.

Eligibility for a Risperdal breast cancer lawsuit is based on the nature and duration of exposure, the diagnosis, and the timing of that diagnosis relative to using Risperdal.

You may qualify to seek compensation in a Risperdal breast cancer lawsuit if:

• You were prescribed Risperdal (risperidone) for six months or longer
• You received a breast cancer diagnosis during or after that period of use
• Your diagnosis involved a hormone-sensitive form of breast cancer
• You were not adequately warned of the potential long-term hormonal risks associated with the medication
• You have documented medical records connecting your Risperdal use and your breast cancer diagnosis
• You took generic risperidone — the active ingredient is identical to brand-name Risperdal and may still qualify

Every case is evaluated individually. If you took Risperdal long-term and have been diagnosed with breast cancer, we recommend speaking with an attorney. This next most important next step costs you nothing. Your consultation is free, confidential, and carries no obligation to move forward.

What Compensation May Be Available in a Risperdal Breast Cancer Lawsuit?

Women who qualify for a Risperdal breast cancer lawsuit may be entitled to compensation for the full range of damages resulting from their diagnosis — not just immediate medical costs, but the long-term financial and personal impact of a cancer diagnosis linked to a medication they were prescribed and trusted.

Recoverable damages may include:

• Medical expenses — past and future, including surgery, chemotherapy, radiation, and ongoing treatment
• Lost income and diminished earning capacity
• Pain and suffering
• Emotional distress and mental anguish
• Loss of enjoyment of life
• Caregiver and home care costs
• Wrongful death damages for families who have lost a loved one

The attorneys at Dolman Law Group have extensive experience handling complex pharmaceutical litigation and understand what it takes to build a strong case against major drug manufacturers.

The value of any individual claim depends on the severity of the diagnosis, the duration of Risperdal use, and the extent of documented harm. A free, confidential consultation is the first step toward understanding what your claim may be worth.

What Research Is Being Cited in These Claims?

Some peer-reviewed endocrine research has examined prolactin-elevating antipsychotic medications and their potential long-term hormonal effects. These studies are part of the broader scientific discussion attorneys reference when evaluating whether risks may have been adequately understood or communicated.

What the Lawsuits Allege

Lawsuits claim patients and physicians may not have been adequately warned about potential long-term risks associated with Risperdal use.

If you or someone you love developed breast cancer after taking Risperdal long-term, you may qualify to pursue compensation through a Risperdal breast cancer lawsuit.

Can Risperdal Increase the Risk of Breast Cancer?

Several major studies have now linked Risperdal and similar prolactin-elevating antipsychotic drugs to increased breast cancer risks in women after long-term use. Researchers believe chronically elevated prolactin levels may stimulate breast tissue in ways that could potentially contribute to hormone-driven cancer development over time.

Importantly, researchers are not saying every woman who takes Risperdal will develop breast cancer. But at a certain point, repeated findings across multiple massive studies stop looking like a random coincidence.

That is exactly why these lawsuits are now starting to gain national attention.

What Is Risperdal?

Risperdal (risperidone) is a prescription antipsychotic developed by Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, used to treat schizophrenia, bipolar disorder, and irritability associated with autism spectrum disorder.

How Risperdal Affects Hormone Levels

The drug works by altering dopamine activity in the brain — but that same mechanism significantly elevates prolactin levels. In some women, those levels remain abnormally elevated for years.

What Is Prolactin and How Is It Related to This Lawsuit?

Prolactin is a hormone directly tied to breast tissue development and milk production. Researchers have spent years studying whether prolactin levels chronically elevated by medications like Risperdal may stimulate breast tissue in ways that contribute to tumor development — and that connection is central to the allegations in these lawsuits.

A History of Hormone-Related Litigation

This is not Risperdal’s first hormone-related controversy. Johnson & Johnson previously faced nationwide litigation alleging Risperdal caused gynecomastia — abnormal breast tissue growth — in boys and young men, with juries awarding substantial verdicts after finding that patients and families were not adequately warned. The current breast cancer concerns raise the same fundamental question: what did the company know, and when?

Is There a Link Between Prolactin and Increased Breast Cancer Risk?

Breast tissue is highly hormone-sensitive. Researchers have long studied whether chronically elevated prolactin may stimulate breast tissue in ways that could contribute to tumor development — particularly hormone-sensitive cancers.

Elevated prolactin alone does not mean someone will develop breast cancer. But across multiple countries and large patient populations, researchers continue finding the same pattern: women taking prolactin-elevating antipsychotics develop breast cancer at significantly higher rates than those who do not. Some of the largest studies involved hundreds of thousands of women. At a certain point, that pattern becomes difficult to dismiss.

What Are High-Prolactin and Medium-Prolactin Antipsychotics?

Antipsychotic medications are classified by how significantly they elevate prolactin levels — high, medium, or low. Risperdal (risperidone) consistently falls into the high-prolactin category, meaning it can elevate prolactin significantly for years during long-term treatment.

Researchers continue finding the strongest breast cancer risk signals surrounding high-prolactin drugs, particularly Risperdal.

High-Prolactin Antipsychotic Medications

The following antipsychotics are generally considered strong prolactin-elevating drugs:

• Risperdal (risperidone)
• Invega (paliperidone)
• Haldol (haloperidol)
• Amisulpride
• Certain older first-generation antipsychotics

Risperdal and Invega are most frequently cited in breast cancer risk research, likely due to the strength and duration of prolactin elevation associated with long-term use.

Medium-Prolactin Antipsychotic Medications

Some antipsychotics appear to elevate prolactin more moderately, including:

• Zyprexa (olanzapine)
• Seroquel (quetiapine)
• Geodon (ziprasidone)

Some studies found increased breast cancer risks among women taking these medications as well, though the strongest signals consistently appeared with high-prolactin drugs.

Lower-Prolactin Antipsychotic Medications

Other antipsychotics appear to have less impact on prolactin levels, including:

• Abilify (aripiprazole)
• Clozaril (clozapine)

Studies found little or no increased breast cancer signal associated with these medications — a pattern researchers believe may help explain why certain antipsychotics appear more prominently in breast cancer research than others.

What Studies Have Linked Risperdal to Breast Cancer?

Multiple large studies involving hundreds of thousands of women across several countries have found statistically significant increases in breast cancer risk among women taking prolactin-elevating antipsychotic medications.

Risperdal was consistently identified among the highest-risk drugs.

Study #1: The Rahman Study Involving More Than 540,000 Women

This study, published by Talha Rahman and colleagues, examined more than 540,000 women in the United States.

The study revealed these results:

• Women taking high-prolactin antipsychotics had a 62% increased relative risk of breast cancer
• Women taking medium-prolactin antipsychotics showed a 54% increased risk
• Risperdal was specifically categorized among the highest prolactin-elevating drugs studied

It is important to recognize that a 62 percent increased relative risk does not mean 62 out of every 100 women developed breast cancer. It means women taking these medications developed breast cancer at significantly higher rates compared to similar women who were not.

The study also found that antipsychotics that did not significantly elevate prolactin did not show the same increased breast cancer pattern. This finding strengthens the theory that prolactin itself may be the mechanism driving increased risk.

Study #2: The 2025 Bird Meta-Analysis

A 2025 meta-analysis conducted by Bird and colleagues combined results from 15 separate studies involving more than one million individuals.

Key findings:

• Any antipsychotic use was associated with a 19% increased breast cancer risk
• Long-term use increases risk further
• High-prolactin drugs, including Risperdal, were associated with a 59% increased risk

Meta-analyses are important because they are conducted by combining results from many prior studies to see whether the same pattern continues appearing repeatedly across different patient populations and datasets.

Again, this meta-analysis is not saying every woman taking Risperdal will develop breast cancer, but from a legal perspective, that repeated pattern is a reason why these lawsuits are gaining traction across the country.

Study #3: The Swedish Solmi Study

Another major study came out of Sweden and examined more than 132,000 women with severe mental health conditions.

Their results found that risk increased with duration of exposure:

• Women exposed for five years or longer showed a 47% increased risk
• Women exposed for one to four years showed elevated breast cancer odds

Women exposed for five years or longer showed a 47% increased risk of developing breast cancer.

Researchers in the Swedish study noted that many women taking these medications already face significant healthcare disparities — including delayed screenings, inconsistent access to care, and difficulty getting symptoms recognized early. For this population, delayed detection can directly affect outcomes. That reality adds further weight to the allegations that patients were not adequately warned of the risks associated with long-term Risperdal use.

Why Researchers Keep Focusing on Risperdal Specifically

Risperdal does not simply appear randomly across these studies. It consistently ranks among the strongest prolactin-elevating drugs and repeatedly shows the strongest breast cancer risk signals.

Researchers are no longer asking whether antipsychotics in general pose a risk — they are asking why the highest prolactin-elevating drugs keep producing the highest risk numbers. For women who took Risperdal for years, that question has direct legal relevance.

Why the Risperdal Breast Cancer Litigation Is Gaining Attention So Quickly

Some pharmaceutical injury lawsuits take years before they gain serious traction nationally.

The Risperdal breast cancer litigation feels different.

And a huge reason why comes down to the fact that researchers are not starting from scratch here.

The prolactin issue tied to Risperdal has already been debated for years because of the earlier gynecomastia litigation involving abnormal breast tissue growth in boys and young men. Researchers already knew Risperdal could significantly elevate prolactin levels long before these newer breast cancer studies started emerging.

Now, multiple studies from multiple countries are continuing to find similar breast cancer risk patterns involving the same category of high-prolactin drugs.

That matters.

Because when researchers keep finding the same signal repeatedly across different patient populations, different healthcare systems, and different datasets, it becomes harder to dismiss those findings as random statistical noise.

And honestly, this is probably one of the biggest reasons attorneys across the country are now paying such close attention to these cases.

This is not one isolated paper making one controversial claim. Researchers are increasingly finding the same troubling pattern over and over again, with the strongest prolactin-elevating drugs, especially Risperdal, repeatedly appearing associated with the strongest breast cancer risk signals.

The Sketchy Past of Risperdal

For many families following the emerging Risperdal breast cancer litigation, one fact keeps coming up again and again. This is not the first time Johnson & Johnson and Janssen Pharmaceuticals have faced allegations involving serious hormone-related side effects tied to Risperdal.

And that history matters.

Because when the same drug keeps generating major safety controversies over the course of years, people naturally start asking whether warning signs were ignored, minimized, or disclosed too late.

The Risperdal Gynecomastia Lawsuits

Long before researchers started publishing studies about possible breast cancer risks in women, Risperdal was already at the center of massive nationwide litigation involving gynecomastia.

Gynecomastia is the abnormal development of breast tissue in males.

Thousands of lawsuits alleged that boys and young men developed significant breast growth after taking Risperdal, sometimes requiring surgical correction and causing severe emotional trauma during adolescence.

The core allegation in many of those lawsuits sounded very familiar to what we are now seeing in the breast cancer litigation discussions, with plaintiffs claiming Johnson & Johnson and Janssen Pharmaceuticals failed to adequately warn patients and doctors about the drug’s prolactin-related hormonal effects.

Some juries returned enormous verdicts.

Over time, Johnson & Johnson and Janssen paid billions collectively resolving Risperdal-related claims and verdicts.

And here is the part many people find difficult to ignore today. The prolactin issue was not hidden from the pharmaceutical industry during those earlier lawsuits. Elevated prolactin levels were already central to the gynecomastia allegations years ago.

Which is exactly why newer breast cancer studies are drawing so much attention now.

Because researchers are essentially asking whether the same hormone disruption linked to abnormal breast tissue growth may also contribute to long-term breast cancer risks in women.

Why the Earlier Risperdal Lawsuits Matter In This Case

The prior Risperdal lawsuits do not automatically prove the current breast cancer allegations.

But they do show something important. Concerns involving prolactin and hormone-related side effects surrounding Risperdal are not new.

This was not some completely unforeseeable issue that suddenly appeared out of nowhere in 2025. Researchers, doctors, and litigants have been debating the effects of elevated prolactin tied to Risperdal for years.

Now, the conversation has shifted toward a much more serious question involving potential cancer risks.

And honestly, this is where many families become frustrated.

Because most consumers assume that if a drug is associated with significant hormonal disruption, especially for years at a time, those risks are being aggressively studied, monitored, and transparently disclosed.

But mass tort litigation across the pharmaceutical industry has repeatedly shown that reality does not always work that way.

What Did Janssen Know and When?

One of the biggest questions likely to emerge in the Risperdal breast cancer litigation is whether Janssen Pharmaceuticals and Johnson & Johnson adequately investigated and disclosed the long-term implications of prolonged prolactin elevation years ago.

The prolactin issue itself is not new.

Earlier Risperdal litigation involving gynecomastia already centered heavily on allegations involving hormone disruption and elevated prolactin levels. Now, newer studies are raising concerns about whether those same hormonal effects may also be connected to increased breast cancer risks in women after long-term exposure.

That does not automatically mean pharmaceutical companies knew Risperdal caused breast cancer decades ago.

But it does raise obvious questions about what was known regarding prolactin-related risks, how aggressively those risks were studied, and whether patients and doctors received the full picture necessary to make truly informed decisions about long-term use.

Janssen Pharmaceuticals and Johnson & Johnson Have Faced Many Mass Tort Allegations In The Past

Risperdal is far from the only major pharmaceutical controversy involving Janssen Pharmaceuticals or its parent company, Johnson & Johnson.

Over the years, the companies have faced repeated allegations involving dangerous products, inadequate warnings, and long-term health risks tied to medications and consumer products used by millions of people.

That does not automatically mean every allegation is true.

But when the same companies repeatedly find themselves at the center of nationwide litigation involving consumer safety concerns, people have every right to start asking difficult questions.

Other Major Johnson & Johnson and Janssen Lawsuits

Johnson & Johnson and its subsidiaries have been tied to numerous major lawsuits and mass torts, including:

• Talcum powder lawsuits alleging links to ovarian cancer and mesothelioma
• Xarelto lawsuits involving allegations of dangerous bleeding risks
• Tylenol lawsuits that allege a link between ASD and ADHD, and the medication
• Elmiron lawsuits involving alleged vision damage and retinal injuries
• Nationwide opioid litigation involving aggressive pharmaceutical marketing practices
• Ongoing pharmaceutical injury and failure-to-warn lawsuits involving multiple products

Again, the issue is not simply that lawsuits exist. Large companies get sued all the time.

The bigger concern is the repeated pattern alleged across many mass tort cases, where consumers claimed they were not adequately warned about serious risks until years after products were already widely prescribed or sold.

That pattern is a huge reason why newer Risperdal breast cancer allegations are being taken seriously so quickly by many attorneys and researchers.

Why This Matters in the Risperdal Breast Cancer Litigation

Cases like this are ultimately about informed consent.

Women deserve the ability to weigh risks and benefits before taking a medication long-term, especially one capable of dramatically altering hormone levels for years.

And most patients are simply not in a position to independently investigate complex pharmaceutical research on their own.

They trust drug manufacturers, regulators, prescribing physicians, and pharmaceutical warning labels to give them accurate information about serious long-term risks.

That trust becomes a major issue in litigation when studies later emerge suggesting those risks may have been larger, more persistent, or more foreseeable than patients realized.

Especially when the medication involved is not something people take temporarily.

For many women, Risperdal became part of their everyday lives for years while they managed severe mental health conditions and tried to function normally.

That is what makes these allegations feel so personal for many families now coming forward.

What Medications Increase Prolactin and Breast Cancer Risk?

Does Risperdal Increase Breast Cancer Risk in Transgender Women?

This is an area that deserves a lot more attention than it currently gets.

Most law firm websites discussing Risperdal and breast cancer completely ignore transgender women altogether, even though the issue may be particularly relevant within the trans community for several important reasons.

Transgender women undergoing feminizing hormone replacement therapy (HRT) develop glandular breast tissue through estrogen exposure. That breast tissue can potentially be affected by many of the same hormone-related cancer risks that researchers study in cisgender women.

At the same time, some hormone regimens may already influence prolactin levels on their own. Adding Risperdal into that equation makes things even more questionable.

Researchers already know Risperdal can significantly elevate prolactin levels, sometimes for years during long-term treatment. So naturally, researchers and attorneys have started asking whether combining hormone therapy with a strong prolactin-elevating antipsychotic could potentially create an even greater risk environment for hormone-sensitive breast cancers.

To be very clear, direct research specifically focused on transgender women taking Risperdal is still limited.

But the biological questions being raised are legitimate.

Because this is not just about identity. It is about breast tissue, hormone exposure, prolactin elevation, and long-term medication use intersecting in ways researchers are still actively trying to understand.

And honestly, this issue may affect more transgender women than many people realize.

Transgender individuals experience significantly higher rates of depression, anxiety, PTSD, and other mental health conditions compared to the general population, often because of discrimination, social stress, healthcare barriers, and family rejection. As a result, transgender patients are statistically more likely to interact with psychiatric healthcare systems and potentially receive medications like Risperdal or similar antipsychotics.

At the same time, transgender patients frequently face barriers to consistent healthcare access, preventive screenings, and early cancer detection.

That combination can create an incredibly dangerous situation, with higher potential exposure to prolactin-elevating medications alongside reduced access to early diagnosis and consistent long-term medical monitoring.

And this is exactly why transparency matters so much.

People deserve to understand potential long-term risks before combining medications and hormone treatments that may significantly alter their endocrine systems for years at a time.

Transgender women who developed breast cancer after long-term Risperdal use may have the same legal rights to pursue compensation as any other patient allegedly harmed by a dangerous or inadequately disclosed medication risk.

Do You Need a Lawyer for a Risperdal Breast Cancer Claim?

Realistically, yes.

Pharmaceutical litigation is incredibly complex, and companies like Johnson & Johnson do not simply roll over when serious injury allegations emerge. These cases usually involve massive amounts of medical records, expert testimony, scientific studies, corporate documents, and highly technical arguments about causation.

And honestly, that is part of what makes pharmaceutical litigation so frustrating for ordinary families.

Most people have no idea how to fight a billion-dollar drug manufacturer while also dealing with cancer treatment, surgeries, financial stress, or the emotional fallout that comes with a breast cancer diagnosis.

Drug companies know that.

That is why experienced mass tort attorneys become so important in cases like this.

An attorney handling a Risperdal breast cancer lawsuit may help:

• Gather prescription and medical records
• Document long-term Risperdal exposure
• Work with medical and scientific experts
• Investigate prolactin-related evidence
• Calculate financial and non-economic damages
• Navigate multidistrict litigation (MDL) proceedings if one develops
• Protect clients from aggressive pharmaceutical defense tactics

And in many cases, there are also strict filing deadlines involved.

Waiting too long to investigate a claim could potentially affect your ability to recover compensation entirely.

Dolman Law Group’s Experience With Dangerous Drug Litigation

At Dolman Law Group, our attorneys have spent years fighting for people harmed by dangerous products, dangerous medications, negligent corporations, and pharmaceutical companies accused of placing profits ahead of consumer safety.

That includes litigation involving defective drugs, toxic exposure, mass torts, and emerging nationwide injury claims long before they become household headlines.

Because honestly, one of the most disturbing parts of mass tort litigation is how often ordinary people only learn about serious risks after thousands of injuries have already occurred.

And pharmaceutical companies know patients are relying on them to be transparent.

People taking medications like Risperdal are not sitting around reading endocrine studies or reviewing prolactin research in medical journals. They are trusting that the medications prescribed to them have been adequately tested, properly monitored, and honestly disclosed.

That trust matters.

Our firm believes consumers deserve access to clear information about potential risks so they can make informed medical decisions with their doctors.

And even when litigation outcomes remain uncertain, these lawsuits still play an important role by forcing dangerous allegations, internal documents, and emerging scientific concerns into public view.

You can see that dynamic playing out right now in other pharmaceutical litigation too.

Take the ongoing Suboxone tooth decay litigation as an example. Even if portions of that litigation ultimately face challenges in court, millions of patients now know something critically important they may not have known before, which is that Suboxone has been linked to severe tooth decay and dental destruction.

That awareness allows people to take precautions, ask questions, seek monitoring, and protect themselves.

The same principle matters here.

Women deserve to know there is growing scientific concern surrounding Risperdal, prolactin elevation, and increased breast cancer risks before they spend years taking a medication that may potentially affect their long-term health.

That is not anti-medication. That is informed consent.

Why Women Deserve to Know About Potential Breast Cancer Risks

No one is saying women should suddenly stop taking prescribed psychiatric medication.

Serious mental health conditions are real, and medications like Risperdal can absolutely help some patients stabilize their lives and function day to day.

But patients also deserve honesty.

They deserve transparency about serious long-term risks being debated within the scientific community, especially when those risks involve cancer and medications designed for prolonged use.

And honestly, this conversation is bigger than just Risperdal.

It raises larger questions about how pharmaceutical companies study long-term hormonal effects, how quickly emerging risks are communicated to the public, and whether vulnerable patient populations are truly being protected the way they should be.

Because the people taking these medications are often already dealing with enormous challenges, including mental illness, financial stress, trauma, healthcare barriers, stigma, and years of medical treatment.

They should not also have to worry that important safety concerns may have been minimized or discovered too late.

At the end of the day, informed consent only works when people are actually informed.

Join the Risperdal Breast Cancer Lawsuit

If you or someone you love developed breast cancer after taking Risperdal or generic risperidone long-term, you may have legal options.

The attorneys at Dolman Law Group are actively monitoring the emerging litigation and investigating potential claims involving prolactin-elevating antipsychotic medications.

Our team understands how overwhelming cases like this can feel, especially while dealing with cancer treatment, medical bills, emotional stress, and uncertainty about what comes next.

You do not have to figure it all out alone.

Contact Dolman Law Group today for a free consultation to learn more about whether you may qualify for a Risperdal breast cancer lawsuit.

---

Article Sources:

1. “Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study” Schizophrenia Bulletin, Volume 50, Issue 6, Published: 30 April 2024, https://doi.org/10.1093/schbul/sbae058
2. “Antipsychotic Use and Risk of Breast Cancer in Women With Schizophrenia: A Nationwide Nested Case-Control Study in Finland” Schizophrenia Bulletin, Volume 47, Issue 4, Published: 2021, https://doi.org/10.1093/schbul/sbae058
3. “Association of Antipsychotic Use With Breast Cancer: A Systematic Review and Meta-analysis of Observational Studies With Over 2 Million Individuals” Epidemiology and Psychiatric Sciences, Volume 31, Published: 2022, https://pubmed.ncbi.nlm.nih.gov/34864772/
4. “Risk of breast cancer with prolactin elevating antipsychotic drugs: An observational study of U.S. women (ages 18–64)” Journal of Clinical Psychopharmacology, Published: 2021, https://doi.org/10.1097/JCP.000000000000140